Skip to main content
. 2022 Jul 8;54(11):1817–1830. doi: 10.1249/MSS.0000000000002989

TABLE 1.

Baseline characteristics of all included patients.

HIIT (n = 13) SHAM (n = 14)
Men/women, n (%) 7 (54)/6 (46) 6 (43)/8 (57)
Age (yr) 52.5 (45.0–60.1) 58.0 (50.1–65.9)
BMI (kg·m−2) 24.3 (21.6–26.9) 24.0 (22.0–26.1)
V̇O2peak (mL·kg−1·min−1) 26.7 (22.3–31.2) 26.3 (22.4–30.3)
Cancer sites
 Colon/rectum, n (%) 4 (30.8) 2 (14.3)
 Stomach, n (%) 3 (23.1) 2 (14.3)
 Melanoma, n (%) 2 (15.4) 1 (7.1)
 Liver, n (%) 1 (7.7) 1 (7.1)
 Pancreas, n (%) 1 (7.7) 0 (0)
 Esophagus, n (%) 1 (7.7) 1 (7.1)
 Ovary, n (%) 1 (7.7) 3 (21.4)
 Myeloma, n (%) 0 (0) 2 (14.3)
 Breast, n (%) 0 (0) 2 (14.3)
 Lung, n (%) 0 (0) 1 (7.1)
UICC stagea
 III, n (%) 1 (7.7) 1 (7.1)
 IV, n (%) 12 (92.3) 11 (78.6)

Numbers are given as mean and 95% confidence intervals and absolute numbers and percentages, respectively.

aTwo myeloma-patients of the SHAM not included in UICC data.